About Nanobody Production
Single-domain antibodies (nanobodies) are becoming increasingly popular as reagents for biomedical research for therapeutic use, and as reagents for diagnostics. The number of publications citing antibodies is increasing each year with over 2,000 publications cited in PubMed to date. This is due, in large part, to their small size, stability, high affinity, high specificity, ease of manipulation, and ease of production.
Through resources provided by the National Institute of General Medical Sciences, our university based Nanobody Production Facility is producing single domain antibodies in alpacas on a fee for service structure. Our facility immunizes alpacas with your protein of interest, amplifies the produced pool of nanobody cDNAs by PCR and generates an immune library, which is then screened by panning against your protein. Positive clones are sequenced, with nanobodies to your target confirmed by ELISA. Deliverables include the nanobodies to your protein produced and purified from E. Coli with 0.5-1 mg of purified nanobody, the nanobody clone, and its sequence. To date we have successfully generated more than 100 nanobodies.
The next round of nanobody production will start in November 2023. The cost to produce a nanobody is currently $9,500. To produce a nanobody to your protein we need 1 to 1.5 mg of purified protein in PBS or HBS at a concentration of 1 mg/ml or higher. We typically deliver your nanobody within 6 months. Frequently we identify more than one nanobody against a particular protein which can be purchased for a nominal cost. A range of derivatives and conjugates are also available.
To request a nanobody produced to your protein please fill out and return this request form, or contact Lou Hersh:
Nanobody Production Services
Includes one verified nanobody clone, its sequence, an expression plasmid and 1 mg of purified nanobody.
Additional Validated Clones
Additional Purified Nanobody
Phagemid library from which nanobody was isolated. Library is produced after one round of panning.
Expression Clone Fused to Reporter
Nanobody Library in Phage Display Vector
Nanobody library in phage display vector from alpaca immunized with supplied antigen
Nanobody Clone Isolated From Naive Alpaca Library
Maturation of Nanobody Isolated from Naive Alpaca library
Please inquire for quote.
Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2. Hou et al. Nat. Struct. Biol. 2020 Sep;27(9):846-854.
Immunization of Alpacas (Lama Pacos) with Protein Antigens and Production of Antigen-specific Single-Domain Antibodies
Immunization of Alpacas (Lama Pacos) with Protein Antigens and Production of Antigen-specific Single-Domain Antibodies. K. Martin Chow, Sidney W. Whiteheart, Jeffrey R. Smiley, Savita Sharma, Kathy Boaz, Meggie J. Coleman, Alvina Maynard, Louis B. Hersh, Craig W. Vander Kooi. J. Vis Exp 2019 Jan 26;(14)
Applications of Nanobodies
Applications of Nanobodies. Muyldermans S. Annu Rev Anim Biosci. 2021 Feb 16;9:401-421.
Nanobodies: A Review of Generation, Diagnostics and Therapeutics
Nanobodies: A Review of Generation, Diagnostics and Therapeutics. Jin BK, Odongo S, Radwanska M, Magez S. Int J Mol Sci. 2023 Mar 22;24(6):5994.
Nanobodies: a new potential for prostate cancer treatment
Nanobodies: a new potential for prostate cancer treatment. Su J, Liu X, Guo S, Zhang J, Wei X, Li X. J Cancer Res Clin Oncol. 2023 Aug;149(9):6703-6710. doi: 10.1007/s00432-022-04515-y.
Nanobodies in the limelight: Multifunctional tools in the fight against viruses
Nanobodies in the limelight: Multifunctional tools in the fight against viruses. Moliner-Morro A, McInerney GM, Hanke L. J Gen Virol. 2022 May;103(5).
NLR immune receptor-nanobody fusions confer plant disease resistance
NLR immune receptor-nanobody fusions confer plant disease resistance. Kourelis J, Marchal C, Posbeyikian A, Harant A, Kamoun S. Science. 2023 Mar 3;379(6635):934-939.
Nanobodies: Robust miniprotein binders in biomedicine
Nanobodies: Robust miniprotein binders in biomedicine. Yong Joon Kim J, Sang Z, Xiang Y, Shen Z, Shi Y. Adv Drug Deliv Rev. 2023 Apr;195:114726.
Nanobodies as Diagnostic and Therapeutic Tools for Cardiovascular Diseases (CVDs)
Nanobodies as Diagnostic and Therapeutic Tools for Cardiovascular Diseases (CVDs). Bocancia-Mateescu LA, Stan D, Mirica AC, Ghita MG, Stan D, Ruta LL. Pharmaceuticals (Basel). 2023 Jun 9;16(6):863.
A few good reasons to use nanobodies for cancer treatment
A few good reasons to use nanobodies for cancer treatment. Jumapili NA, Zivalj M, Barthelmess RM, Raes G, De Groof TWM, Devoogdt N, Stijlemans B, Vincke C, Van Ginderachter JA. Eur J Immunol. 2023 Jun 27:e2250024.
Orally delivered single-domain antibodies against gastrointestinal pathogens
Orally delivered single-domain antibodies against gastrointestinal pathogens. Petersson M, Thrane SW, Gram L, Muyldermans S, Laustsen AH. Trends Biotechnol. 2023 Jul;41(7):875-886. doi: 10.1016/j.tibtech.2023.01.015.
Controlling ion channel function with renewable recombinant antibodies.
Controlling ion channel function with renewable recombinant antibodies. Cole craft HM, Trimmer JS. J Physiol. 2022 May;600(9):2023-2036.